European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation

Europace

Volumn 15, Issue 5, 2013, Pages 625-651

  Heidbuchel, Hein ^a   Verhamme, Peter ^a   Alings, Marco ^b   Antz, Matthias ^c   Hacke, Werner ^d   Oldgren, Jonas ^e   Sinnaeve, Peter ^a   Camm, A John ^f   Kirchhof, Paulus ^g,h  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b AMPHIA HOSPITAL   (Netherlands)

^c KLINIKUM OLDENBURG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UPPSALA UNIVERSITY   (Sweden)

^f ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^g UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^h UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Anticoagulation; Atrial fibrillation; Bleeding; Pharmacology; Stroke

Indexed keywords

ACENOCOUMAROL; AMIODARONE; ANTACID AGENT; APIXABAN; ATORVASTATIN; CARBAMAZEPINE; CLARITHROMYCIN; CYCLOSPORIN; DABIGATRAN; DIGOXIN; DILTIAZEM; DRONEDARONE; EDOXABAN; ERYTHROMYCIN; FLUCONAZOLE; HEMOCLOT; HEPARIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; LOW MOLECULAR WEIGHT HEPARIN; PHENOBARBITAL; PHENYTOIN; PROTON PUMP INHIBITOR; QUINIDINE; RIFAMPICIN; RITONAVIR; RIVAROXABAN; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ABLATION THERAPY; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BARE METAL STENT; BLOOD CLOTTING TEST; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIAC PATIENT; CARDIOVERSION; CAROTID ENDARTERECTOMY; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG METABOLISM; DRUG SAFETY; DRUG UPTAKE; FOLLOW UP; FOOD DRUG INTERACTION; FOOD INTAKE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART RATE; HEART RHYTHM; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOADING DRUG DOSE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONVALVULAR ATRIAL FIBRILLATION; PARTIAL THROMBOPLASTIN TIME; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTHROMBIN TIME; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOLOGY; EUROPE; HEART VALVE DISEASES; THROMBOSIS;

EID: 84877301336     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut083     Document Type: Article

References (101)

1. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12: 1360-420.
2. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. Focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14: 1385-413.
3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361: 1139-51.
4. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364: 806-17.
5. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective a Nticoa Gulation with factor x A next GEneration in Atrial Fibrillation- Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010;160: 635-41.
6. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365: 883-91.
7. Hendriks JM, de Wit R, Crijns HJ, Vrijhoef HJ, Prins MH, Pisters R et al. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur Heart J 2012;33: 2692-9.
8. Berti D, Hendriks JM, Brandes A, Deaton C, Crijns HJ, Camm AJ et al. A proposal for interdisciplinary, nurse-coordinated atrial fibrillation expert programmes as a way to structure daily practice. Eur Heart J 2013;doi: 10.1093/eurheartj/eht096. [first published online March 21, 2013].
9. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010;50: 743-53.
10. Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 2008;6: 1542-9.
11. van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. Am. J. Med. 2012;125: 417-20.
12. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103: 1116-27.
13. Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012;107: 838-47.
14. Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 2010;32: 673-9.
15. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb and haemost 2012;107: 985-97.
16. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deepvein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011;50: 675-86.
17. Matsushima N, Lee F, Sato T, Weiss D, Mendell J. Absolute bioavailability of edoxaban in healthy subjects. AAPS J 2011;13:S2(abstract).
18. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos, Biol Fate Chem 2009;37: 74-81.
19. Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010; 38: 448-58.
20. Mendell J, Tachibana M, Shi M, Kunitada S. Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers. J Clin Pharmacol 2011;51: 687-94.
21. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006;46: 549-58.
22. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36: 386-99.
23. Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008;47: 47-59.
24. Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011;9: 2168-75.
25. Moore KT, Plotnikov AN, Thyssen A, Vaccaro N, Ariyawansa J, Burton PB. Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban. J Cardiovasc Pharmacol 2011;58: 581-8.
26. Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther 2011;338: 372-80.
27. Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Brit J Clin Pharmacol (2013; EPub ahead of print; doi 10.1111/bcp.12075).
28. Lahaye SA, Gibbens SL, Ball DG, Day AG, Olesen JB, Skanes AC. A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation. Eur Heart J 2012;33: 2163-71.
29. Stangier J, Rathgen K, Stahle H, Reseski K, Kornicke T, Roth W. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs, Drugs Dev Other Interv 2009;9: 59-68.
30. Mendell J, Noveck R, Zahir H, Lee F, Petrushin V, Rubets I et al. The effect of quinidine and verapamil, P glycoprotein/CYP3A4/5 inhibitors, on edoxaban pharmacokinetics and pharmacodynamics. Basic Clin Pharmacol Toxicol 2010; 107: 2848 (abstract).
31. Kubitza D, Mueck W, Becka M. No interaction between rivaroxaban - a novel, oral direct factor Xa inhibitor - and atorvastatin. Pathophysiol Haemost Thromb 2008;36:(A40 Abstract P062).
32. Stangier J, Stahle H, Rathgen K, Roth W, Reseski K, Kornicke T. Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, With Coadministration of Digoxin. J Clin Pharmacol 2011 (Epub ahead of print; doi: 10.1177/0091270010393342).
33. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. No interaction between the novel, oral direct factor Xa inhibitor BAY 59-7939 and digoxin. J Clin Pharmacol 2006;46: 702 (Abstract 11).
34. Hartter S, Koenen-Bergmann M, Sharma A, Nehmiz G, Lemke U, Timmer W et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Brit J Clin Pharmacol 2012;74: 490-500.
35. Yasaka M, Inoue H, Kawai Y, Yamaguchi T, Uchiyama S, Matsumoto M et al. Randomized, parallel group, warfarin control, multicenter phase II study evaluating safety of DU-176b in Japanese subjects with non-valvular atrial fibrillation (NVAF). J Thromb Haemost 2009;7(Suppl 2):PP-WE-196 (abstract).
36. Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial. Circulation 2013;127: 634-40.
37. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366: 9-19.
38. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365: 699-708.
39. Bae JP, Dobesh PP, Klepser DG, Anderson JD, Zagar AJ, McCollam PL et al. Adherence and dosing frequency of common medications for cardiovascular patients. Am J Manag Care 2012;18: 139-46.
40. Laliberte F, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 2012;29: 675-90.
41. Olesen JB, Lip GYH, Kamper A-L, Hommel K, Kober L, Lane DA et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367: 625-35.
42. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012;33: 2821-30.
43. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients With nonvalvular atrial fibrillation: validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (An Ticoagulation and Risk factors In Atrial fibrillation) Study Cohorts. Circulation 2013;127: 224-32.
44. Camm AJ, Savelieva I. 'R' for 'renal' and for 'risk': refining risk stratification for stroke in atrial fibrillation. Circulation 2013;127: 169-71.
45. Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 2011;57: 1339-48.
46. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32: 2387-94.
47. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123: 2363-72.
48. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an openlabel, parallel-group, single-centre study. Clin Pharmacokinet 2010;49: 259-68.
49. Ridout G, de la Motte S, Niemczyk S, Sramek P, Johnson L, Jin J et al. Effect of renal function on edoxaban pharmacokinetics (PK) and on population PK/PK-PD model. J Clin Pharmacol 2009;49: 1124 (abstract).
50. Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Brit J Clin Pharmacol 2010;70: 703-12.
51. Kubitza D, Becka M, Roth A, Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008;24: 2757-65.
52. Levi M, Eerenberg E, Kamphuisen PW. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemos 2011;9: 1705-12.
53. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW. Recombinant factor VIIa (r FVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012;119: 2172-4.
54. Wanek MR, Horn ET, Elapavaluru S, Baroody SC, Sokos G. Safe use of hemodialysis for dabigatran removal before cardiac surgery. Ann Pharmacother 2012;46: e21.
55. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011;42: 3594-9.
56. Lambourne MD, Eltringham-Smith LJ, Gataiance S, Arnold DM, Crowther MA, Sheffield WP. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J Thromb Haemos 2012;10: 1830-40.
57. Pragst I, Dörr B, Kaspereit F, Krege W, Zeitler SH, van Ryn J. Beriplex P/N reverses bleeding in an acute renal injury model after dabigatran overdose in rabbits. Pathophysiol Haemost Thromb 2010;37(Suppl 1):A94.
58. Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemos 2012;10: 1841-8.
59. Godier A, Miclot A, Le Bonniec B, Durand M, Fischer AM, Emmerich J et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012;116: 94-102.
60. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124: 1573-9.
61. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G. Effect of nonspecific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemos 2012; 108: 217-24.
62. Escolar G, Arellano-Rodrigo E, Reverter JC, Villalta J, Sanz V, Molina P et al. Reversal of apixaban induced alterations of hemostasis by different coagulation factor concentrates: studies in vitro with circulating human blood. AHA Emerging Science Series, June 20, 2012. Circulation 2012;126: 520-1 (Abstract).
63. van Ryn J, Ruehl D, Priepke H, Hauel N, Wienen W. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate. Haematologica 2008;93(Suppl 1): 148.
64. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S et al. Periprocedural bleeding and thromboembolic events with dabigatran compared to warfarin: results from the RE-LY Randomized Trial. Circulation 2012;126: 343-8.
65. Sie P, Samama CM, Godier A, Rosencher N, Steib A, Llau JV et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis 2011;104: 669-76.
66. Torn M, Rosendaal FR. Oral anticoagulation in surgical procedures: risks and recommendations. Br J Haematol 2003;123: 676-82.
67. Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, Swarup V et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2012;59: 1168-74.
68. Kaseno K, Naito S, Nakamura K, Sakamoto T, Sasaki T, Tsukada N et al. Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. Circ J 2012;76: 2337-42.
69. Snipelisky D, Kauffman C, Prussak K, Johns G, Venkatachalam K, Kusumoto F. A comparison of bleeding complications post-ablation between warfarin and dabigatran. J Interv Card Electrophysiol 2012;35: 29-33.
70. Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol 2012;23: 264-8.
71. Kim JS, She F, Jongnarangsin K, Chugh A, Latchamsetty R, Ghanbari H et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm (EPub ahead of print, March 2013, doi: 10.1016/j.hrthm.2012.12.011).
72. Lopes RD, Pieper KS, Horton JR, Al-Khatib SM, Newby LK, Mehta RH et al. Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart 2008; 94: 867-73.
73. Lopes RD, Elliott LE, White HD, Hochman JS, Van de Werf F, Ardissino D et al. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. Eur Heart J 2009;30: 2019-28.
74. Lopes RD, Starr A, Pieper CF, Al-Khatib SM, Newby LK, Mehta RH et al. Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. Am J Med 2010;123: 134-40.
75. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook Jr. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005;143: 241-50.
76. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347: 969-74.
77. Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 2002;105: 557-63.
78. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. J Am Coll Cardiol 2001;37: 475-84.
79. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised doubleblind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997;350: 389-96.
80. Sorensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jorgensen C et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: A retrospective analysis of nationwide registry data. Lancet 2009;374: 1967-74.
81. Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: A nationwide cohort study. Circulation 2012;126: 1185-93.
82. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;doi:pii: 10.1016/S0140-6736(12)62177-1 [Epub ahead of print].
83. Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: A randomized, double-blind, phase II trial. Eur Heart J 2011;32: 2781-9.
84. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361: 1045-57.
85. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357: 2001-15.
86. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012;172: 397-402.
87. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 2012;125: 669-76.
88. Karjalainen PP, Vikman S, Niemela M, Porela P, Ylitalo A, Vaittinen MA et al. Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. Eur Heart J 2008;29: 1001-10.
89. Mehta SR, Granger CB, Eikelboom JW, Bassand JP, Wallentin L, Faxon DP et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007;50: 1742-51.
90. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB et al. Effects of fondaparinux onmortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295: 1519-30.
91. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32: 2999-3054.
92. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol 2012;59: 1413-25.
93. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). Brit Med J 2006;333: 1091.
94. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008;29: 2909-45.
95. Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011;123: 131-6.
96. Flaker G, Lopes R, Al-Khatib S, Hermosillo A, Thomas L, Zhu J et al. Apixaban and warfarin are associated with a low risk of stroke following cardioversion for AF: Results from the ARISTOTLE Trial. Eur Heart J 2012;33(Abstract Supplement): 686.
97. Piccini JP, Stevens S. Outcomes following cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET-AF trial. Circulation 2012;126(Abstract Supplement, Abstract A19281).
98. Radberg JA, Olsson JE, Radberg CT. Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment. Stroke 1991;22: 571-6.
99. Morgenstern LB, Hemphill JC 3rd, Anderson C, Becker K, Broderick JP, Connolly ES Jr. et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010;41: 2108-29.
100. Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012;43: 1511-7.
101. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33: 1500-10.